August 6, 2019

Novocure to Participate in Three Upcoming Investor Conferences

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in three upcoming investor conferences. Pritesh Shah, Novocure’s Chief Commercial Officer, will participate in the Wedbush PacGrow Healthcare Conference on August 14, 2019, in New York City. Mr. Shah’s presentation will begin at 8:35 a.m. Read More
learn more
August 6, 2019

Novocure to Participate in Three Upcoming Investor Conferences

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in three upcoming investor conferences. Pritesh Shah, Novocure’s Chief Commercial Officer, will participate in the Wedbush PacGrow Healthcare Conference on August 14, 2019, in New York City. Mr. Shah’s presentation will begin at 8:35 a.m. Read More
learn more
July 25, 2019

Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update

Quarterly net revenues of $86.7 million, representing 41 percent growth versus the second quarter 2018 The NovoTTF-100L™ System FDA approved to treat malignant pleural mesothelioma in combination with standard chemotherapies, Novocure’s first FDA-approved torso indication Medicare released final local coverage determination and fee schedule amount providing coverage… Read More
learn more
July 25, 2019

Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update

Quarterly net revenues of $86.7 million, representing 41 percent growth versus the second quarter 2018 The NovoTTF-100L™ System FDA approved to treat malignant pleural mesothelioma in combination with standard chemotherapies, Novocure’s first FDA-approved torso indication Medicare released final local coverage determination and fee schedule amount providing coverage… Read More
learn more
July 22, 2019

Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 10 oral presentations and a special session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology (EMB) Conference,… Read More
learn more
July 22, 2019

Novocure Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 10 oral presentations and a special session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology (EMB) Conference,… Read More
learn more
July 18, 2019

CMS Establishes 2019 Monthly Fee Schedule Amount for Optune®

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website. The announcement by CMS… Read More
learn more
July 18, 2019

CMS Establishes 2019 Monthly Fee Schedule Amount for Optune®

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website. The announcement by CMS… Read More
learn more
July 18, 2019

Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local coverage determination (LCD) providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) effective September 1, 2019. The final LCD and a… Read More
learn more
July 18, 2019

Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local coverage determination (LCD) providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) effective September 1, 2019. The final LCD and a… Read More
learn more